Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ESC Congress

Discover the latest news and 2024 updates on managing hypertension, heart failure, coronary syndromes, atrial fibrillation and arterial disease. 
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in:

16-05-2024 | Rhabdomyosarcoma

What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?

Authors: Shinji Miwa, MD, PhD, Katsuhiro Hayashi, MD, PhD, Yuta Taniguchi, MD, PhD, Yohei Asano, MD, Satoru Demura, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 6/2024

Login to get access

Opinion Statement

Rhabdomyosarcoma, a soft tissue sarcoma commonly observed in childhood, requires multidisciplinary treatment, including surgical tumor resection, chemotherapy, and radiation therapy. Although long-term survival can be expected in patients with localized rhabdomyosarcoma, the clinical outcomes in patients with metastatic or unresectable rhabdomyosarcoma remain unsatisfactory. To improve the outcomes of rhabdomyosarcoma, it is important to explore effective systemic treatments for metastatic rhabdomyosarcoma. Currently, multiagent chemotherapy comprising vincristine, actinomycin D, and ifosfamide/cyclophosphamide remains standard systemic treatment for rhabdomyosarcoma. On the other hand, new treatment, such as immune checkpoint inhibitors and molecular targeted drugs, have demonstrated superior clinical outcomes compared to those of standard treatments in various type of malignancies. Therefore, it is necessary to assess the efficacies of these treatments in patients with rhabdomyosarcoma. Recent clinical studies have shown efficacies and safeties of temozolomide combined with vincristine/irinotecan, olaratumab combined with doxorubicin or vincristine/irinotecan, and long-term maintenance therapy. Furthermore, basic researches demonstrated new therapeutic targets. Future studies using these approaches are required to assess their clinical significances.
Literature
1.
Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. Cancer. 2009;115(18):4218–26.PubMedCrossRef
2.
Xia SJ, Rajput P, Strzelecki DM, Barr FG. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein. Lab Invest. 2007;87(4):318–25.PubMedCrossRef
3.
Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001;20(40):5736–46.PubMedCrossRef
4.
Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO classification of tumours of the soft tissues and bone. Lyon: IARC Press; 2013.
5.
Barr FG, Qualman SJ, Macris MH, et al. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res. 2002;62(16):4704–10.PubMed
6.
Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res. 2004;64(16):5539–45.PubMedCrossRef
7.
Dantonello TM, Int-Veen C, Schuck A, et al. Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma. Pediatr Blood Cancer. 2013;60(8):1267–73.PubMedCrossRef
8.
Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59(1):5–10.PubMedPubMedCentralCrossRef
9.
Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26(14):2384–9.PubMedPubMedCentralCrossRef
10.
Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma–a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2003;21(1):78–84.PubMedCrossRef
11.
Weigel BJ, Lyden E, Anderson JR, et al. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group. J Clin Oncol. 2016;34(2):117–22.PubMedCrossRef
12.
13.
Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report Cancer. 1988;61(2):209–20.PubMed
14.
Maurer HM, Gehan EA, Beltangady M, et al. The intergroup rhabdomyosarcoma study-II. Cancer. 1993;71(5):1904–22.PubMedCrossRef
15.
Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol. 1999;17(12):3706–19.PubMedCrossRef
16.•
Sparber-Sauer M, Ferrari A, Kosztyla D, et al. Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults. Pediatr Blood Cancer. 2022;69(9):e29691. This reference is of importance because shows long-term outcomes of standard chemotherapy (vincristine, ifosfamide, adriamycin, and dactinomycin [VAIA]) versus an intensified six-drug regimen (carboplatin, epirubicin, vincristine, dactinomycin, ifosfamide, and etoposide [CEVAIE]) in patients with high-risk RMS, extraskeletal Ewing’s sarcoma, and undifferentiated sarcoma.PubMedCrossRef
17.••
Defachelles AS, Bogart E, Casanova M, et al. J Clin Oncol. 2021;39(27):2979–90. This reference is of major importance because shows efficacy and safety of vincristine/irinotecan with or without temozolomide (VIT and VI, respectively) in patients with relapsed/refractory RMS. In this study, the VIT group showed significantly better overall survival than the VI group (P < 0.01).PubMedCrossRef
18.
Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011;71(9):3196–201.PubMedPubMedCentralCrossRef
19.
Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67(14):6745–52.PubMedCrossRef
20.
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269–73.PubMedCrossRef
21.•
Metts JL, Trucco M, Weiser DA, et al. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. Cancer Med. 2023;12(4):4270–81. This reference is of importance because shows a result of a phase 1 study of metformin in combination with vincristine, irinotecan, and temozolomide in pediatric patients with refractory solid and central nervous system tumors. Based on the results, the addition of metformin to the chemotherapy regimen appears to be tolerable and effective.PubMedCrossRef
22.•
Mascarenhas L, Ogawa C, Laetsch TW, et al. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Med. 2021;10(3):843–56. This reference is of importance because shows results of a phase 1 study of olaratumab with or without chemotherapy in patients with relapsed/refractory solid tumors.PubMedPubMedCentralCrossRef
23.
Klingebiel T, Boos J, Beske F, et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer. 2008;50(4):739–45.PubMedCrossRef
24.
Tramsen L, Bochennek K, Sparber-Sauer M, et al. Pediatric Patients with Stage IV Rhabdomyosarcoma Significantly Benefit from Long-Term Maintenance Therapy: Results of the CWS-IV 2002 and the CWS DOK IV 2004-Trials. Cancers (Basel) 2023;15(7):2050.
25.
Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res. 2008;14(5):1286–90.PubMedCrossRef
26.
Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 1994;54(4):903–7.PubMed
27.
Houghton PJ, Morton CL, Gorlick R, et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther. 2010;9(1):101–12.PubMedPubMedCentralCrossRef
28.
Oberoi S, Qumseya A, Xue W, et al. Feasibility of combining temsirolimus to vincristine, dactinomycin, cyclophosphamide, and vincristine and irinotecan chemotherapy for children with intermediate-risk rhabdomyosarcoma: A report from Children's Oncology Group. Pediatr Blood Cancer. 2023;e30436. Online ahead of print.
29.
Fellous A, Ohayon R, Vacassin T, et al. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol. 1989;16(2):9–14.PubMed
30.
Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 2000;60(18):5045–51.PubMed
31.
32.
Allen-Rhoades W, Lupo PJ, Scheurer ME, et al. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis. Cancer Med. 2023;12(9):10222–9.PubMedPubMedCentralCrossRef
33.
El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ. 1990;1(7):325–31.PubMed
34.
Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, Helman LJ. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer. 1998;76(2):223–7.PubMedCrossRef
35.
Wang W, Kumar P, Wang W, et al. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res. 1998;58(19):4426–33.PubMed
36.
Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008;68(19):8039–48.PubMedPubMedCentralCrossRef
37.
Wagner LM, Fouladi M, Ahmed A, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015;62(3):440–4.PubMedCrossRef
38.
39.
Demetri GD, Lo Russo P, MacPherson IR, et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009;15(19):6232–40.PubMedCrossRef
40.•
Akshintala S, Sundby RT, Bernstein D, et al. Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma. Clin Cancer Res. 2023;29(17):3329–39. This reference is of importance because shows results of a phase 1 trial of ganitumab combined with dasatinib in patients with relapsed/refractory alveolar or embryonal RMS.PubMedPubMedCentralCrossRef
41.
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.PubMedCrossRef
42.
43.
Shern JF, Selfe J, Izquierdo E, et al. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. J Clin Oncol. 2021;39(26):2859–71.PubMedPubMedCentralCrossRef
44.
Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524–8.PubMedPubMedCentralCrossRef
45.
Murugan AK, Dong J, Xie J, Xing M. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle. 2009;8(13):2122–4.PubMedCrossRef
46.•
Eckstein OS, Allen CE, Williams PM, et al. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022;40(20):2235–45. This reference is of importance because shows results of a phase 2 study on the MEK inhibitor selumetinib in patients with tumors harboring gene alterations in MAPK pathway.PubMedPubMedCentralCrossRef
47.•
Cole KA, Ijaz H, Surrey LF, et al. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. Cancer. 2023;129(14):2245–55. This reference is of importance because shows results of a phase 2 study of adavosertib combined with irinotecan in pediatric patients with recurrent neuroblastoma, medulloblastoma/central nervous embryonal tumors, and RMS.PubMedCrossRef
48.
Hodi FS. Overcoming immunological tolerance to melanoma: Targeting CTLA-4. Asia Pac J Clin Oncol. 2010;6(Suppl 1):S16-23.PubMed
49.
Geoerger B, Zwaan CM, Marshall LV, et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study. Lancet Oncol. 2020;21(1):134–44.PubMedCrossRef
50.
Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020;21(1):121–33.PubMedCrossRef
51.
Bouffet E, Larouche V, Campbell BB, et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol. 2016;34(19):2206–11.PubMedCrossRef
52.
Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020;21(4):541–50.PubMedPubMedCentralCrossRef
53.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535–46.PubMedCrossRef
54.
Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64.PubMedCrossRef
55.••
Davis KL, Fox E, Isikwei E, et al. A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412. Clin Cancer Res. 2022;28(23):5088–97. This reference is of major importance because shows results of a phase 1/2 study of nivolumab in combination with ipilimumab in patients with recurrent/refractory solid tumors, including Ewing’s sarcoma, RMS, and osteosarcoma. Based on the results, treatment with 3 mg/kg nivolumab and 1 mg/kg ipilimumab appears to have some clinical activity and is tolerable in patients with solid tumors, including RMS.PubMedPubMedCentralCrossRef
56.
Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013;12(7):1322–31.PubMedCrossRef
57.
Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–55.PubMedCrossRef
58.•
Geoerger B, Morland B, Jimenez I, et al. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies. Eur J Cancer. 2021;153:142–52. This refence is of importance because shows results of a phase 1 study of regorafenib in pediatric patients with recurrent/refractory solid tumors, including three RMS.PubMedCrossRef
59.
60.
Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4(2):216–31.PubMedPubMedCentralCrossRef
61.
62.
Garcia N, Del Pozo V, Yohe ME, et al. Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS(Q61X) Mutant Rhabdomyosarcoma. Mol Cancer Ther. 2022;21(1):170–83.PubMedCrossRef
63.
Renshaw J, Taylor KR, Bishop R, et al. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res. 2013;19(21):5940–51.PubMedCrossRef
64.
Yohe ME, Gryder BE, Shern JF, et al. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. Sci Transl Med 2018;10(448):4470.
65.
Hebron KE, Wan X, Roth JS, et al. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models. Clin Cancer Res. 2023;29(2):472–87.PubMedPubMedCentralCrossRef
66.
Marics I, Padilla F, Guillemot JF, Scaal M, Marcelle C. FGFR4 signaling is a necessary step in limb muscle differentiation. Development. 2002;129(19):4559–69.PubMedCrossRef
67.
Gryder BE, Yohe ME, Chou HC, et al. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discov. 2017;7(8):884–99.PubMedPubMedCentralCrossRef
68.
Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med. 2001;7(6):673–9.PubMedPubMedCentralCrossRef
69.
Wu JT, Cheuk A, Isanogle K, et al. Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma. Cancers (Basel) 2023;15(16):4034.
70.
Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58(3):488–520.PubMedCrossRef
71.
Karami-Tehrani F, Moeinifard M, Aghaei M, Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012;43(6):470–5.PubMedCrossRef
72.
Zhang X, Yan G, Ji J, et al. PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells. J Cell Biochem. 2012;113(8):2738–43.PubMedCrossRef
73.
Das A, Durrant D, Mitchell C, et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A. 2010;107(42):18202–7.PubMedPubMedCentralCrossRef
74.
Urla C, Stagno MJ, Fuchs J, Warmann SW, Schmid E. Combination therapy of doxorubicin and Sildenafil inhibits the growth of pediatric rhabdomyosarcoma. J Cancer Res Clin Oncol. 2023;149(6):2513–22.PubMedCrossRef
75.
Urosevic M, Nikolic L, Gajic I, Nikolic V, Dinic A, Miljkovic V. Curcumin: Biological Activities and Modern Pharmaceutical Forms. Antibiotics (Basel) 2022; 11(2):135.
76.
Giordano A, Tommonaro G. Curcumin and Cancer. Nutrients 2019; 11(10):2376.
77.
Salucci S, Bavelloni A, Stella AB, et al. The Cytotoxic Effect of Curcumin in Rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling. Nutrients 2023; 15(3):740.
78.
Park H, Park S, Yang YH, Choi KY. Microbial synthesis of violacein pigment and its potential applications. Crit Rev Biotechnol. 2021;41(6):879–901.PubMedCrossRef
79.
Milosevic E, Stanisavljevic N, Boskovic S, et al. Antitumor activity of natural pigment violacein against osteosarcoma and rhabdomyosarcoma cell lines. J Cancer Res Clin Oncol. 2023;149(13):10975–87.PubMedCrossRef
80.
Shackelford RE, Mayhall K, Maxwell NM, Kandil E, Coppola D. Nicotinamide phosphoribosyltransferase in malignancy: a review. Genes Cancer. 2013;4(11–12):447–56.PubMedPubMedCentralCrossRef
81.
McKay-Corkum GB, Collins VJ, Yeung C, et al. Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models. Clin Cancer Res. 2023;29(21):4479–91.PubMedPubMedCentralCrossRef
Metadata
Title
What are the Optimal Systemic Treatment Options for Rhabdomyosarcoma?
Authors
Shinji Miwa, MD, PhD
Katsuhiro Hayashi, MD, PhD
Yuta Taniguchi, MD, PhD
Yohei Asano, MD
Satoru Demura, MD, PhD
Publication date
16-05-2024
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 6/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-024-01206-3

Other articles of this Issue 6/2024

Current Treatment Options in Oncology 6/2024 Go to the issue

ReviewPaper

Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome

ReviewPaper

Neoadjuvant Photodynamic Therapy: An Updated Therapeutic Approach for Non-Melanoma Skin Cancers

ReviewPaper

Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors

ReviewPaper

Management of dysphagia in head and neck cancer

Correction

Correction to: Intraperitoneal and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer

ReviewPaper

Genetic predisposition to sarcoma: what should clinicians know?